

5 October 2007

Securities and Exchange Commission  
Division of Corporate Finance  
Office of International Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
U.S.A.

RECEIVED  
27 OCT 17 A 9:42  
U.S. SECURITIES AND EXCHANGE COMMISSION



07027330

Attention: Mr. Elliot Staffin

Re: *Elliot*  
~~Viralytics Limited~~  
12g3-2(b) Information  
File No. 82-34945

**SUPPL**

Dear Mr. Staffin

Enclosed please find information that Viralytics Limited is required to furnish to the Securities and Exchange Commission pursuant to Rule 12g3-2(b) of the Securities Exchange Act of 1934, as amended.

The attached documents are being furnished with the understanding that:

- they will not be deemed "filed" with the Securities and Exchange Commission or otherwise subject to the liabilities of Section 18 of the Securities Exchange Act; and
- neither this letter nor the furnishing of such documents shall constitute an admission for any purpose that Viralytics Limited is subject to the Securities Exchange Act.

If you have any questions or comments, please call the undersigned on telephone 61 2 9499 3200.

*Bryan Dulhunty*  
Bryan Dulhunty  
Executive Chairman

**PROCESSED**

*B* OCT 23 2007

THOMSON  
FINANCIAL

*lee*  
10/17

Viralytics Ltd ABN 42 010 657 351  
www.viralytics.com

t +61 2 9499 3200 f +61 2 9499 3300  
8/33 Ryde Road Pymble NSW 2113  
Australia



# **VIRALYTICS LTD**

**ONCOLYTIC VIRUSES**

**A NEW HOPE FOR CANCER TREATMENT**

RECEIVED

2007 OCT 17 A 9:42

SENDER'S MAIL  
CORPORATE FINANCE

**ASX Release**

**Date: 3 October 2007**

**Subject: Date of Annual General Meeting**

---

In accordance with listing rule 3.13 the Company wishes to advise that the Annual General Meeting of the Company will be held at 10am on Tuesday 27th November 2007 in the Adelaide/Brisbane Suite, The Menzies, Sydney, Accor Hotels, 14 Carrington Street, Sydney NSW 2000.

The Notice of Meeting and the Annual Report will be distributed to all shareholders on or around 27 October 2007.

**Bryan Dulhunty**  
**Executive Chairman**

---

**About Viralytics Ltd.** Viralytics is listed on the Australian Stock Exchange (ASX code: VLA), Viralytics ADR trades under VRACY on the OTC market in the USA. Viralytics' principal asset is the intellectual property relating to CAVATAK™, an Oncolytic Virus technology. CAVATAK™ is the trade name for Viralytics' proprietary formulation of the Cocksackievirus Type A21 (CVA21). CVA21 is a human virus that occurs naturally in the community. CVA21 attaches to the outside of a cell, using a specific 'receptor' on the cell's surface (like a key fitting a lock). CVA21 uses two receptors to infect cells, intercellular adhesion molecule-1 (ICAM-1) and/or decay accelerating factor (DAF). Both of these receptor proteins have been demonstrated to be highly expressed on multiple cancer types, including: melanoma, prostate cancer, breast cancer, multiple myeloma and others

**END**

8/33 Ryde Road, Pymble NSW 2073 Australia

PO Box 1045, Pymble Business Centre, Pymble NSW 2073 Australia

P 61 2 9499 3200 F 61 2 9499 3300

E [viralytics@viralytics.com](mailto:viralytics@viralytics.com) W [www.viralytics.com](http://www.viralytics.com)

VIRALYTICS LTD ABN 12 010 657 351